PA
NTST

PharVision Advisers’s NETSTREIT Corp NTST Stock Holding History

PharVision Advisers’s Portfolio NTST Stock Details NTST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,134
Closed -$285K – 474
2025
Q4 		$285K Buy
+16,134
New +$294K 0.14% 302

Other funds holding NTST

Cohen & Steers
Cohen & Steers New York $63.2B AUM 17.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PharVision Advisers's NTST Position: Q1 2026 in Review

PharVision Advisers sold out of NETSTREIT Corp (NTST) in Q1 2026, closing a stake of 16,134 shares — an estimated $285K sold.

PharVision Advisers first reported a position in NTST in Q4 2025 and held it in 1 quarter. The position peaked at $285K in Q4 2025. 254 funds tracked by Wall St. Rank hold NTST as of Q1 2026.

  • PharVision Advisers reported no remaining NETSTREIT Corp position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 16,134 NETSTREIT Corp shares in Q1 2026, an estimated $285K.
  • PharVision Advisers first reported a position in NETSTREIT Corp in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's NETSTREIT Corp position peaked at $285K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held NETSTREIT Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.